ABEO Live signals | Maximize Profits with Getagraph.com

BUY 102488 min ago

@ $6.00

Issued: 14 Feb 2024 @ 14:22

Return: -46.83%

Previous signal: Feb 14 - 13:08

Previous signal: Sell

Return: -5.73 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	1.10M
Average Volume	492 553
Market Cap	87.26M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.500 ) 2024-05-09
Last Dividend	$3 706.25 ( 2000-03-31 )
Next Dividend	$0 ( N/A )
P/E	-1.260
ATR14	$0.0110 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Vazzano Joseph Walter	Sell	703	Common stock
2024-03-04	O'malley Brendan M.	Sell	183	Common stock
2024-02-06	Seshadri Vishwas	Buy	20 000	Common Stock
2024-01-17	Alvino Mark	Sell	7 084	Common Stock
2023-10-16	Seshadri Vishwas	Sell	181	Common Stock

INSIDER POWER
81.82
Last 95 transactions
Buy: 4 747 231 \| Sell: 745 827

Volume Correlation

Long: 0.08 (neutral)

Short: 0.64 (weak)

Signal:(62.271) Neutral

Abeona Therapeutics Inc Correlation

10 Most Positive Correlations
NVDA	0.94
COOL	0.939
BOTZ	0.938
OPRA	0.935
SVAC	0.932
AVGO	0.924
SMCI	0.923
ADVM	0.923
DFH	0.922
TQQQ	0.921

10 Most Negative Correlations
AMRB	-0.953
LWAC	-0.916
NETE	-0.915
SOPA	-0.913
ONCR	-0.909
PHCF	-0.907
SRAC	-0.9
PRDO	-0.89
QTEK	-0.888
AGFS	-0.887

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Abeona Therapeutics Inc Correlation - Currency/Commodity

0.12
( neutral )

0.07
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.20
( neutral )

-0.24
( neutral )

Abeona Therapeutics Inc Financials

Annual	2023
Revenue:	$3.50M
Gross Profit:	$302 000 (8.63 %)
EPS:	$-2.53

Q4	2023
Revenue:	$0
Gross Profit:	$-721 000 (0.00 %)
EPS:	$-0.650

Q3	2023
Revenue:	$0
Gross Profit:	$-751 000 (0.00 %)
EPS:	$-0.480

Q2	2023
Revenue:	$3.50M
Gross Profit:	$2.66M (76.06 %)
EPS:	$-0.920

Financial Reports:

No articles found.

Abeona Therapeutics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Abeona Therapeutics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$3 706.25	2000-03-31
Last Dividend	$3 706.25	2000-03-31
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$3 706.25	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-25)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2000	$3.00	0.03%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-15.48	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.847	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-3.34	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.10	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.103	1.500	4.98	7.47	[0.2 - 2]
debtRatioTTM	0.0844	-1.500	8.59	-10.00	[0 - 0.6]
interestCoverageTTM	-115.31	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.448	2.00	-0.483	-0.965	[0 - 30]
freeCashFlowPerShareTTM	-1.461	2.00	-0.731	-1.461	[0 - 20]
debtEquityRatioTTM	0.364	-1.500	8.54	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0863	1.000	-1.895	-1.895	[0.2 - 0.8]
operatingProfitMarginTTM	-13.77	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-6.85	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0547	0.800	-2.97	-2.38	[0.5 - 2]
Total Score				-2.42

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.495	1.000	-0.252	0	[1 - 100]
returnOnEquityTTM	-3.34	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.461	2.00	-0.487	-1.461	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.448	2.00	-0.483	-0.965	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0693	1.500	-2.87	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-10.57	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.65

Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.